MUMBAI/NEW DELHI, March 29 -- Dr. Reddy's Laboratories will have 30 days to sell existing stock of its semaglutide drug branded "Olymviq" before discontinuing the name, after the Delhi High Court recorded the company's undertaking to cease its use in a trademark dispute with Novo Nordisk.

The reprieve allows the company to clear inventory while shifting to a new brand, "OLYMRA", in a fast-growing market for semaglutide-based diabetes and weight-loss treatments.

In a written order dated 27 March, reviewed by Mint, the court noted that Dr. Reddy's will cease all use of the mark, including manufacture, sale, supply, distribution, promotion, advertising and any commercial use, both online and offline, while being permitted to exhaust its ex...